Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AGER | Q15109 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407532 | 0.88 | ADAMTS4 (0.36) | ADAMTS4HTR7MEN1POLBKMT2A | |
| SCHEMBL6769197 | 0.88 | ADAMTS4 (0.36) | ADAMTS4HTR7MEN1POLBKMT2A | |
| SCHEMBL6767719 | 0.77 | MMP2 (0.40) | MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL6325647 | 0.76 | MMP2 (0.39) | MEN1KMT2AALDH1A1 | |
| SCHEMBL6325908 | 0.74 | ADAMTS4 (0.58) | ADAMTS4MEN1POLBKMT2ALMNA | |
| SCHEMBL6325911 | 0.74 | ADAMTS4 (0.58) | ADAMTS4MEN1POLBKMT2ALMNA | |
| SCHEMBL6324360 | 0.70 | SIGMAR1 (0.42) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6322302 | 0.70 | TDO2 (0.43) | ADAMTS4ALDH1A1 | |
| SCHEMBL6324860 | 0.69 | CA12 (0.49) | MEN1POLBKMT2ALMNAHTT | |
| SCHEMBL6324864 | 0.69 | CA12 (0.49) | MEN1POLBKMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | ADAMTS4 33/4885HTR7 3825/4885MEN1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.